Literature DB >> 20601294

Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.

Conor C Lynch1.   

Abstract

Bone remodeling is a delicate balancing act between the bone matrix synthesizing osteoblasts and bone resorbing osteoclasts. Active bone metastases typically subvert this process to generate lesions that are comprised of extensive areas of pathological osteogenesis and osteolysis. The resultant increase in bone matrix remodeling enhances cytokine/growth factor bioavailability thus creating a vicious cycle that stimulates tumor progression. Given the extent of matrix remodeling occurring in the tumor-bone microenvironment, the expression of matrix metalloproteinases (MMPs) would be expected, since collectively they have the ability to degrade all components of the extracellular matrix (ECM). However, in addition to being "matrix bulldozers", MMPs control the bioavailability and bioactivity of factors such as RANKL and TGFβ that have been described as crucial for tumor-bone interaction, thus implicating MMPs as key regulators of the vicious cycle of bone metastases.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601294     DOI: 10.1016/j.bone.2010.06.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  37 in total

1.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

2.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

3.  Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1-17.

Authors:  J S Frieling; G Shay; V Izumi; S T Aherne; R G Saul; M Budzevich; J Koomen; C C Lynch
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.

Authors:  Arturo Araujo; Leah M Cook; Conor C Lynch; David Basanta
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

5.  Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion.

Authors:  Feng-Qi Nie; Quan Zhu; Tong-Peng Xu; Yan-Fen Zou; Min Xie; Ming Sun; Rui Xia; Kai-Hua Lu
Journal:  Tumour Biol       Date:  2014-05-04

6.  Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.

Authors:  Antonella Chiechi; Chiara Novello; Giovanna Magagnoli; Emanuel F Petricoin; Jianghong Deng; Maria S Benassi; Piero Picci; Iosif Vaisman; Virginia Espina; Lance A Liotta
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

7.  Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Authors:  Wen Liu; Carolyn J Vivian; Amanda E Brinker; Kelsey R Hampton; Evi Lianidou; Danny R Welch
Journal:  Cancer Microenviron       Date:  2014-06-18

Review 8.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

9.  Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.

Authors:  Amalia Conti; Virginia Espina; Antonella Chiechi; Giovanna Magagnoli; Chiara Novello; Laura Pazzaglia; Irene Quattrini; Piero Picci; Lance A Liotta; Maria Serena Benassi
Journal:  Clin Exp Metastasis       Date:  2013-07-23       Impact factor: 5.150

10.  Runx2-Smad signaling impacts the progression of tumor-induced bone disease.

Authors:  Xuhui Zhang; Jacqueline Akech; Gillian Browne; Stacey Russell; John J Wixted; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Int J Cancer       Date:  2014-08-05       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.